Incyte (NASDAQ:INCY) is set to release its earnings data before the market opens on Tuesday, October 30th. Analysts expect Incyte to post earnings of $0.19 per share for the quarter.
Incyte (NASDAQ:INCY) last released its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.26 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.22. Incyte had a positive return on equity of 1.74% and a negative net margin of 5.92%. The business had revenue of $521.50 million during the quarter, compared to analyst estimates of $510.70 million. During the same quarter last year, the company posted ($0.06) EPS. Incyte’s revenue for the quarter was up 59.8% on a year-over-year basis. On average, analysts expect Incyte to post $0 EPS for the current fiscal year and $2 EPS for the next fiscal year.
NASDAQ:INCY opened at $65.18 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.34 and a quick ratio of 4.32. Incyte has a 1-year low of $60.22 and a 1-year high of $117.95. The firm has a market capitalization of $14.04 billion, a P/E ratio of 101.84 and a beta of 1.12.
A number of research firms recently weighed in on INCY. Zacks Investment Research lowered Incyte from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Cantor Fitzgerald reiterated a “hold” rating and issued a $74.00 price target (up previously from $73.00) on shares of Incyte in a research report on Sunday. Oppenheimer set a $70.00 price target on Incyte and gave the company a “hold” rating in a research report on Tuesday, July 17th. BidaskClub lowered Incyte from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 11th. Finally, Royal Bank of Canada lowered Incyte from an “outperform” rating to a “sector perform” rating and decreased their price target for the company from $76.00 to $74.00 in a research report on Tuesday, June 26th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and fourteen have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $94.48.
In other news, EVP Paula J. Swain sold 10,000 shares of Incyte stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $73.21, for a total transaction of $732,100.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Barry P. Flannelly sold 1,000 shares of Incyte stock in a transaction dated Wednesday, October 3rd. The shares were sold at an average price of $70.00, for a total value of $70,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 31,000 shares of company stock valued at $2,202,100 over the last 90 days. Corporate insiders own 17.20% of the company’s stock.
Incyte Company Profile
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.
Further Reading: What is a stock buyback?
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.